Ngā hua rapu kaituhi

1

Precision medicine in pediatric oncology mā Stefan Burdach, Mike‐Andrew Westhoff, Maximilian Steinhauser, Klaus‐Michael Debatin

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
2

Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin mā Selim Corbacioglu, Mehtap Kılıç, Mike‐Andrew Westhoff, Dirk Reinhardt, Simone Fulda, Klaus‐Michael Debatin

I whakaputaina 2006

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
3

Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptor– and Drug-Induced Apoptosis mā Daniela Opel, Mike‐Andrew Westhoff, Ariane Bender, Veit Braun, Klaus‐Michael Debatin, Simone Fulda

I whakaputaina 2008

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
4

Src-Mediated Phosphorylation of Focal Adhesion Kinase Couples Actin and Adhesion Dynamics to Survival Signaling mā Mike‐Andrew Westhoff, Bryan Serrels, Valerie J. Fincham, Margaret C. Frame, Neil O. Carragher

I whakaputaina 2004

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
5

A Novel Role for FAK as a Protease-Targeting Adaptor Protein mā Neil O. Carragher, Mike‐Andrew Westhoff, Valerie J. Fincham, Michael D. Schaller, Margaret C. Frame

I whakaputaina 2003

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
6

Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells mā Timo Burster, Rebecca Traut, Zhanerke Yermekkyzy, Katja M. Mayer, Mike‐Andrew Westhoff, Joachim Bischof, Uwe Knippschild

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
7

Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma mā Georg Karpel‐Massler, Chiaki Tsuge Ishida, Yiru Zhang, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Markus D. Siegelin

I whakaputaina 2017

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
8

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma mā Chiaki Tsuge Ishida, Elena Bianchetti, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Georg Karpel‐Massler, Markus D. Siegelin

I whakaputaina 2017

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
9

Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells mā Joachim Bischof, Mike‐Andrew Westhoff, Johanna Wagner, Marc‐Eric Halatsch, Stephanie Trentmann, Uwe Knippschild, Christian Rainer Wirtz, Timo Burster

I whakaputaina 2017

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
10

Sequential Dosing in Chemosensitization: Targeting the PI3K/Akt/mTOR Pathway in Neuroblastoma mā Mike‐Andrew Westhoff, Najmeh Faham, Daniela Marx, Lisa Nonnenmacher, Claudia Jennewein, Stefanie Enzenmüller, Patrick Gonzalez, Simone Fulda, Klaus‐Michael Debatin

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
11

Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems mā Trang Nguyen, Yiru Zhang, Enyuan Shang, Chang Shu, Catarina M. Quinzii, Mike‐Andrew Westhoff, Georg Karpel‐Massler, Markus D. Siegelin

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
12

v-Src-Induced Modulation of the Calpain-Calpastatin Proteolytic System Regulates Transformation mā Neil O. Carragher, Mike‐Andrew Westhoff, Deborah Riley, David A. Potter, Previn Dutt, John S. Elce, Peter A. Greer, Margaret C. Frame

I whakaputaina 2002

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
13

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo mā Georg Karpel‐Massler, Maïmouna Bâ, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin

I whakaputaina 2015

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
14

Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo mā Georg Karpel‐Massler, Doruntina Ramani, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin

I whakaputaina 2016

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
15

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy mā Hannah A. Strobel, Tim Baisch, Rahel Fitzel, Katharina Schilberg, Markus D. Siegelin, Georg Karpel‐Massler, Klaus‐Michael Debatin, Mike‐Andrew Westhoff

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
16

RIST: A potent new combination therapy for glioblastoma mā Lisa Nonnenmacher, Mike‐Andrew Westhoff, Simone Fulda, Georg Karpel‐Massler, Marc‐Eric Halatsch, Jens Engelke, Thomas Simmet, Selim Corbacioglu, Klaus‐Michael Debatin

I whakaputaina 2014

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
17

A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy mā Mike‐Andrew Westhoff, Georg Karpel‐Massler, Oliver Brühl, Stefanie Enzenmüller, Katia La Ferla-Brühl, Markus D. Siegelin, Lisa Nonnenmacher, Klaus‐Michael Debatin

I whakaputaina 2014

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
18

Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo mā Georg Karpel‐Massler, Matei A. Banu, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin

I whakaputaina 2016

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
19

TRAIL (TNF-related apoptosis-inducing ligand) regulates adipocyte metabolism by caspase-mediated cleavage of PPARgamma mā Michaela Keuper, Ingrid Wernstedt Asterholm, Philipp E. Scherer, Mike‐Andrew Westhoff, Peter Möller, Klaus‐Michael Debatin, Gudrun Strauß, Martin Wabitsch, Pamela Fischer‐Posovszky

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
20

The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair mā Mike‐Andrew Westhoff, J. A. Kandenwein, Sabine Karl, Sri HariKrishna Vellanki, V. Braun, Adriana Eramo, Gregor Antoniadis, Klaus‐Michael Debatin, Simone Fulda

I whakaputaina 2009

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:

Precision medicine in pediatric oncology mā Stefan Burdach, Mike‐Andrew Westhoff, Maximilian Steinhauser, Klaus‐Michael Debatin

Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin mā Selim Corbacioglu, Mehtap Kılıç, Mike‐Andrew Westhoff, Dirk Reinhardt, Simone Fulda, Klaus‐Michael Debatin

Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptor– and Drug-Induced Apoptosis mā Daniela Opel, Mike‐Andrew Westhoff, Ariane Bender, Veit Braun, Klaus‐Michael Debatin, Simone Fulda

Src-Mediated Phosphorylation of Focal Adhesion Kinase Couples Actin and Adhesion Dynamics to Survival Signaling mā Mike‐Andrew Westhoff, Bryan Serrels, Valerie J. Fincham, Margaret C. Frame, Neil O. Carragher

A Novel Role for FAK as a Protease-Targeting Adaptor Protein mā Neil O. Carragher, Mike‐Andrew Westhoff, Valerie J. Fincham, Michael D. Schaller, Margaret C. Frame

Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells mā Timo Burster, Rebecca Traut, Zhanerke Yermekkyzy, Katja M. Mayer, Mike‐Andrew Westhoff, Joachim Bischof, Uwe Knippschild

Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma mā Georg Karpel‐Massler, Chiaki Tsuge Ishida, Yiru Zhang, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Markus D. Siegelin

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma mā Chiaki Tsuge Ishida, Elena Bianchetti, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Georg Karpel‐Massler, Markus D. Siegelin

Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells mā Joachim Bischof, Mike‐Andrew Westhoff, Johanna Wagner, Marc‐Eric Halatsch, Stephanie Trentmann, Uwe Knippschild, Christian Rainer Wirtz, Timo Burster

Sequential Dosing in Chemosensitization: Targeting the PI3K/Akt/mTOR Pathway in Neuroblastoma mā Mike‐Andrew Westhoff, Najmeh Faham, Daniela Marx, Lisa Nonnenmacher, Claudia Jennewein, Stefanie Enzenmüller, Patrick Gonzalez, Simone Fulda, Klaus‐Michael Debatin

Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems mā Trang Nguyen, Yiru Zhang, Enyuan Shang, Chang Shu, Catarina M. Quinzii, Mike‐Andrew Westhoff, Georg Karpel‐Massler, Markus D. Siegelin

v-Src-Induced Modulation of the Calpain-Calpastatin Proteolytic System Regulates Transformation mā Neil O. Carragher, Mike‐Andrew Westhoff, Deborah Riley, David A. Potter, Previn Dutt, John S. Elce, Peter A. Greer, Margaret C. Frame

Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis <i>in vitro</i> and <i>in vivo</i> mā Georg Karpel‐Massler, Doruntina Ramani, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy mā Hannah A. Strobel, Tim Baisch, Rahel Fitzel, Katharina Schilberg, Markus D. Siegelin, Georg Karpel‐Massler, Klaus‐Michael Debatin, Mike‐Andrew Westhoff

RIST: A potent new combination therapy for glioblastoma mā Lisa Nonnenmacher, Mike‐Andrew Westhoff, Simone Fulda, Georg Karpel‐Massler, Marc‐Eric Halatsch, Jens Engelke, Thomas Simmet, Selim Corbacioglu, Klaus‐Michael Debatin

A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy mā Mike‐Andrew Westhoff, Georg Karpel‐Massler, Oliver Brühl, Stefanie Enzenmüller, Katia La Ferla-Brühl, Markus D. Siegelin, Lisa Nonnenmacher, Klaus‐Michael Debatin

Inhibition of deubiquitinases primes glioblastoma cells to apoptosis <i>in vitro</i> and <i>in vivo</i> mā Georg Karpel‐Massler, Matei A. Banu, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin

The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair mā Mike‐Andrew Westhoff, J. A. Kandenwein, Sabine Karl, Sri HariKrishna Vellanki, V. Braun, Adriana Eramo, Gregor Antoniadis, Klaus‐Michael Debatin, Simone Fulda

Ngā hua rapu - Mike‐Andrew Westhoff

Precision medicine in pediatric oncology mā Stefan Burdach, Mike‐Andrew Westhoff, Maximilian Steinhauser, Klaus‐Michael Debatin

Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin mā Selim Corbacioglu, Mehtap Kılıç, Mike‐Andrew Westhoff, Dirk Reinhardt, Simone Fulda, Klaus‐Michael Debatin

Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptor– and Drug-Induced Apoptosis mā Daniela Opel, Mike‐Andrew Westhoff, Ariane Bender, Veit Braun, Klaus‐Michael Debatin, Simone Fulda

Src-Mediated Phosphorylation of Focal Adhesion Kinase Couples Actin and Adhesion Dynamics to Survival Signaling mā Mike‐Andrew Westhoff, Bryan Serrels, Valerie J. Fincham, Margaret C. Frame, Neil O. Carragher

A Novel Role for FAK as a Protease-Targeting Adaptor Protein mā Neil O. Carragher, Mike‐Andrew Westhoff, Valerie J. Fincham, Michael D. Schaller, Margaret C. Frame

Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells mā Timo Burster, Rebecca Traut, Zhanerke Yermekkyzy, Katja M. Mayer, Mike‐Andrew Westhoff, Joachim Bischof, Uwe Knippschild

Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma mā Georg Karpel‐Massler, Chiaki Tsuge Ishida, Yiru Zhang, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Markus D. Siegelin

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma mā Chiaki Tsuge Ishida, Elena Bianchetti, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Georg Karpel‐Massler, Markus D. Siegelin

Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells mā Joachim Bischof, Mike‐Andrew Westhoff, Johanna Wagner, Marc‐Eric Halatsch, Stephanie Trentmann, Uwe Knippschild, Christian Rainer Wirtz, Timo Burster

Sequential Dosing in Chemosensitization: Targeting the PI3K/Akt/mTOR Pathway in Neuroblastoma mā Mike‐Andrew Westhoff, Najmeh Faham, Daniela Marx, Lisa Nonnenmacher, Claudia Jennewein, Stefanie Enzenmüller, Patrick Gonzalez, Simone Fulda, Klaus‐Michael Debatin

Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems mā Trang Nguyen, Yiru Zhang, Enyuan Shang, Chang Shu, Catarina M. Quinzii, Mike‐Andrew Westhoff, Georg Karpel‐Massler, Markus D. Siegelin

v-Src-Induced Modulation of the Calpain-Calpastatin Proteolytic System Regulates Transformation mā Neil O. Carragher, Mike‐Andrew Westhoff, Deborah Riley, David A. Potter, Previn Dutt, John S. Elce, Peter A. Greer, Margaret C. Frame

Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis <i>in vitro</i> and <i>in vivo</i> mā Georg Karpel‐Massler, Doruntina Ramani, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy mā Hannah A. Strobel, Tim Baisch, Rahel Fitzel, Katharina Schilberg, Markus D. Siegelin, Georg Karpel‐Massler, Klaus‐Michael Debatin, Mike‐Andrew Westhoff

RIST: A potent new combination therapy for glioblastoma mā Lisa Nonnenmacher, Mike‐Andrew Westhoff, Simone Fulda, Georg Karpel‐Massler, Marc‐Eric Halatsch, Jens Engelke, Thomas Simmet, Selim Corbacioglu, Klaus‐Michael Debatin

A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy mā Mike‐Andrew Westhoff, Georg Karpel‐Massler, Oliver Brühl, Stefanie Enzenmüller, Katia La Ferla-Brühl, Markus D. Siegelin, Lisa Nonnenmacher, Klaus‐Michael Debatin

Inhibition of deubiquitinases primes glioblastoma cells to apoptosis <i>in vitro</i> and <i>in vivo</i> mā Georg Karpel‐Massler, Matei A. Banu, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin

The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair mā Mike‐Andrew Westhoff, J. A. Kandenwein, Sabine Karl, Sri HariKrishna Vellanki, V. Braun, Adriana Eramo, Gregor Antoniadis, Klaus‐Michael Debatin, Simone Fulda

Ngā utauta rapu:

Ngā marau whai pānga